What it is

Prohibitin-targeting peptidomimetic carried on metabolic research catalogs. (Sold as a single compound)

Also known as

FTPP · APT · Prohibitin-targeting peptide · Adipotide

Overview

Adipotide (FTPP) is a prohibitin-targeting peptidomimetic listed on metabolic research-supply catalogs. Preclinical literature explores vascular and adipose-depot targeting concepts rather than classical incretin signaling.

It is sold here as a single research compound for laboratory investigation of adipose-related endpoints. Left Turn Adventures supplies this compound for laboratory and research use only.

Proven benefits

Note: Preclinical / literature endpoints for labs — not established human treatment benefits. Not a protocol.

• Prohibitin-pathway targeting endpoints in adipose models

• • White-adipose vascular and depot-related readouts in preclinical work

• • Body-composition markers in metabolic research designs

• • Apoptosis/angiogenesis-adjacent measures in adipose tissue models

• • Comparative metabolic catalog studies versus incretin ligands

Results timeline

Note: Illustrative research-observation windows — not a clinical schedule. No dosing.

• Week 1–2: Early receptor-engagement and appetite/energy-signaling readouts in model systems; compound exposure establishing.

• • Week 3–4: Clearer metabolic and satiety-pathway markers in short preclinical windows.

• • Month 2–3: More stable body-composition and glucose/lipid-related endpoints where studied.

• • Month 3–6: Sustained metabolic-signaling observations in longer research designs.

Footer RUO

The catalog, not a clinic

For laboratory and research use only. Not for human or animal consumption. Products are sold solely to qualified researchers and licensed laboratories. No dosing or reconstitution on this page.